NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NDA FilingPrimeCPositive

AI Analysis

Summary

NeuroSense announced plans to submit PrimeC for New Drug Submission to Health Canada for ALS treatment, following alignment with regulators on the NDS pathway and supported by PARADIGM trial data demonstrating survival benefit.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Planned submission to Health Canada following alignment on NDS pathway; supported by additional PARADIGM data showing survival benefit

Importance:7/10

Sentiment:

0.70

ALSregulatoryCanadaNDS pathwaysurvival benefit

Related Companies

$NRS

Read the original article

Published by PR Newswire Biotech on July 22, 2026 12:30 PM

Read Original